Protagen launches GMP protein analysis services
Protagen is one of the first biotechnology companies in Germany to meet the requirements for approval from the USA Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) to offer analytical methods within the guidelines for manufacturers of therapeutic proteins.
Commenting on the announcement, Christoph Huels, CEO of Protagen said: "Being awarded GMP certification is a great achievement for Protagen and underlines our strategy to provide protein analysis services of the highest quality. We are committed to supporting our customers in their effort to meet the industry's increasingly strict controls and regulations, and we are delighted to be able to offer the flexibility of tailoring research programmes and providing protein services under GMP where required."
Other news from the department politics & laws
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.